Barclays PLC reduced its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 87.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,062 shares of the company's stock after selling 14,143 shares during the quarter. Barclays PLC's holdings in argenx were worth $1,268,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Whipplewood Advisors LLC bought a new position in shares of argenx during the 4th quarter worth $37,000. Global Retirement Partners LLC boosted its stake in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after buying an additional 48 shares during the period. FIL Ltd purchased a new position in shares of argenx during the fourth quarter worth about $38,000. Jones Financial Companies Lllp increased its holdings in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares during the last quarter. Finally, Huntington National Bank raised its position in argenx by 1,133.3% during the fourth quarter. Huntington National Bank now owns 74 shares of the company's stock valued at $46,000 after purchasing an additional 68 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the stock. Guggenheim upped their price objective on shares of argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Piper Sandler boosted their price objective on shares of argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research report on Tuesday, January 7th. Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a research note on Monday, March 17th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Finally, Truist Financial restated a "buy" rating and set a $700.00 price target (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, argenx presently has an average rating of "Moderate Buy" and a consensus target price of $699.28.
Check Out Our Latest Stock Report on argenx
argenx Stock Performance
Shares of argenx stock opened at $649.67 on Monday. The stock's fifty day moving average is $598.32 and its 200 day moving average is $612.34. The stock has a market cap of $39.67 billion, a P/E ratio of -738.26 and a beta of 0.57. argenx SE has a one year low of $352.77 and a one year high of $678.21.
argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. Analysts predict that argenx SE will post 3.13 EPS for the current year.
argenx Company Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Recommended Stories
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
